Consistent with the proapoptotic effect of Evo in lung cancer CSCs, treatment with Evo induced apoptosis in NSCLC cells in a dose-dependent manner, as indicated by increases in PARP and caspase-3 cleavage (Figure 5G), chromatin condensation (Figure 5H), and the annexin V-positive cell population (Figure 5I). The gene discussed is ANXA5; the disease is non-small cell lung carcinoma.